Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE
Virtus Investment Advisers LLC invested $85,000 in Maze Therapeutics, acquiring 6,940 shares. Other institutional investors have also recently taken positions in the company. Analysts have given Maze Therapeutics a consensus "Buy" rating, with a target price of $38.57. The company's stock opened at $37.75, with a market cap of $1.82 billion. Maze Therapeutics focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases.
Virtus Investment Advisers LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,940 shares of the company's stock, valued at approximately $85,000.
- Biotech Breakouts: 3 Stocks With Massive Upside Potential
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. purchased a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $226,000. Goldman Sachs Group Inc. acquired a new position in shares of Maze Therapeutics in the first quarter worth about $145,000. Nuveen LLC acquired a new position in shares of Maze Therapeutics in the first quarter worth about $125,000. Bank of New York Mellon Corp purchased a new stake in shares of Maze Therapeutics during the 1st quarter worth about $190,000. Finally, Octagon Capital Advisors LP acquired a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $5,153,000.
Get Maze Therapeutics alerts:
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on MAZE. Wedbush upped their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research note on Friday, November 7th. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $27.00 to $37.00 and gave the stock an "overweight" rating in a research note on Monday, September 29th. BTIG Research increased their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 15th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $38.57.
Read Our Latest Research Report on MAZE
Insider Buying and Selling
In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a filing with the SEC, which is available at this link.
Maze Therapeutics Stock Down 0.7%
Shares of MAZE opened at $37.75 on Monday. The stock has a fifty day simple moving average of $30.51 and a two-hundred day simple moving average of $19.98. The company has a market capitalization of $1.82 billion and a PE ratio of -1.81. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $38.85.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.08.
Maze Therapeutics Company Profile
(Free Report)We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Read More
- Five stocks we like better than Maze Therapeutics
- How to invest in marijuana stocks in 7 steps
- Bath & Body Works Hits Multi-Year Lows: Bargain or Trap?
- Airline Stocks - Top Airline Stocks to Buy Now
- Worried About Inflation? These 3 ETFs Offer Real Protection
- How to Choose Top Rated Stocks
- Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally
Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Maze Therapeutics Right Now?
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
